Susquehanna International Group’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-8,900
| Closed | -$256K | – | 11995 |
|
|
2023
Q1 | $256K | Sell |
8,900
-33,100
| -79% | -$985K | ﹤0.01% | 10069 |
|
|
2022
Q4 | $1.24M | Buy |
42,000
+3,700
| +10% | +$105K | ﹤0.01% | 5718 |
|
|
2022
Q3 | $912K | Buy |
+38,300
| New | +$881K | ﹤0.01% | 6873 |
|
|
2022
Q2 | – | Sell |
-8,300
| Closed | -$208K | – | 12808 |
|
|
2022
Q1 | $208K | Buy |
+8,300
| New | +$253K | ﹤0.01% | 11145 |
|
|
2021
Q4 | – | Sell |
-6,000
| Closed | -$255K | – | 13056 |
|
|
2021
Q3 | $255K | Buy |
+6,000
| New | +$247K | ﹤0.01% | 10966 |
|
|
2021
Q2 | – | Sell |
-14,800
| Closed | -$604K | – | 12506 |
|
|
2021
Q1 | $604K | Sell |
14,800
-16,100
| -52% | -$611K | ﹤0.01% | 9043 |
|
|
2020
Q4 | $1.4M | Buy |
+30,900
| New | +$1.17M | ﹤0.01% | 5900 |
|
|
2020
Q3 | – | Sell |
-54,500
| Closed | -$2.06M | – | 10496 |
|
|
2020
Q2 | $2.06M | Buy |
54,500
+33,000
| +153% | +$1.09M | ﹤0.01% | 4446 |
|
|
2020
Q1 | $622K | Buy |
21,500
+15,300
| +247% | +$619K | ﹤0.01% | 6451 |
|
|
2019
Q4 | $321K | Buy |
6,200
+2,000
| +48% | +$116K | ﹤0.01% | 7883 |
|
|
2019
Q3 | $231K | Sell |
4,200
-9,900
| -70% | -$508K | ﹤0.01% | 8819 |
|
|
2019
Q2 | $573K | Sell |
14,100
-12,800
| -48% | -$467K | ﹤0.01% | 6995 |
|
|
2019
Q1 | $813K | Buy |
26,900
+19,400
| +259% | +$664K | ﹤0.01% | 5395 |
|
|
2018
Q4 | $252K | Sell |
7,500
-90,800
| -92% | -$3.28M | ﹤0.01% | 7321 |
|
|
2018
Q3 | $4.15M | Sell |
98,300
-31,600
| -24% | -$1.25M | ﹤0.01% | 2902 |
|
|
2018
Q2 | $4.16M | Buy |
129,900
+94,400
| +266% | +$3.89M | ﹤0.01% | 2954 |
|
|
2018
Q1 | $1.76M | Buy |
35,500
+29,100
| +455% | +$1.64M | ﹤0.01% | 4159 |
|
|
2017
Q4 | $345K | Sell |
6,400
-8,500
| -57% | -$470K | ﹤0.01% | 7345 |
|
|
2017
Q3 | $864K | Sell |
14,900
-24,600
| -62% | -$1.29M | ﹤0.01% | 5536 |
|
|
2017
Q2 | $1.95M | Buy |
39,500
+18,100
| +85% | +$834K | ﹤0.01% | 3960 |
|
|
2017
Q1 | $930K | Buy |
21,400
+9,800
| +84% | +$468K | ﹤0.01% | 5275 |
|
|
2016
Q4 | $568K | Sell |
11,600
-4,300
| -27% | -$199K | ﹤0.01% | 6713 |
|
|
2016
Q3 | $761K | Sell |
15,900
-21,500
| -57% | -$1.06M | ﹤0.01% | 5312 |
|
|
2016
Q2 | $2.01M | Sell |
37,400
-7,900
| -17% | -$372K | ﹤0.01% | 3570 |
|
|
2016
Q1 | $2.03M | Sell |
45,300
-14,000
| -24% | -$568K | ﹤0.01% | 3740 |
|
|
2015
Q4 | $2.26M | Sell |
59,300
-5,000
| -8% | -$191K | ﹤0.01% | 3789 |
|
|
2015
Q3 | $2.05M | Sell |
64,300
-7,400
| -10% | -$258K | ﹤0.01% | 4239 |
|
|
2015
Q2 | $2.37M | Buy |
71,700
+21,600
| +43% | +$770K | ﹤0.01% | 4351 |
|
|
2015
Q1 | $2.06M | Buy |
50,100
+12,700
| +34% | +$513K | ﹤0.01% | 4272 |
|
|
2014
Q4 | $1.52M | Sell |
37,400
-41,600
| -53% | -$1.63M | ﹤0.01% | 5005 |
|
|
2014
Q3 | $2.9M | Buy |
79,000
+6,500
| +9% | +$281K | ﹤0.01% | 3960 |
|
|
2014
Q2 | $3.36M | Buy |
72,500
+19,700
| +37% | +$876K | ﹤0.01% | 3716 |
|
|
2014
Q1 | $2.17M | Buy |
52,800
+39,800
| +306% | +$1.48M | ﹤0.01% | 4206 |
|
|
2013
Q4 | $496K | Buy |
13,000
+3,800
| +41% | +$117K | ﹤0.01% | 6709 |
|
|
2013
Q3 | $220K | Buy |
+9,200
| New | +$207K | ﹤0.01% | 7634 |
|
Other funds holding ANIK
CP
VCM
BFM
CM
Susquehanna International Group's ANIK Position: Q1 2026 in Review
Susquehanna International Group increased its Anika Therapeutics (ANIK) stake by 31% in Q1 2026, buying an estimated $87.5K and bringing the position to 31,751 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #9888.
Susquehanna International Group first reported a position in ANIK in Q4 2013 and has held it in 34 quarters since. The position peaked at $2.78M in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.
- Susquehanna International Group held 31,751 shares of Anika Therapeutics worth $460K as of Q1 2026.
- Susquehanna International Group bought 7,541 Anika Therapeutics shares in Q1 2026, an estimated $87.5K.
- Anika Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9888 holding.
- Susquehanna International Group first reported a position in Anika Therapeutics in Q4 2013 and has held it in 34 quarters since.
- Susquehanna International Group's Anika Therapeutics position peaked at $2.78M in Q3 2019.
- 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.